跳至主要内容
临床试验/ISRCTN10003823
ISRCTN10003823已完成3 期

A randomised controlled trial of light therapy, negative ion therapy and fluoxetine in non-seasonal major depression

niversity of British Columbia (Canada)0 个研究点目标入组 216 人开始时间: 2009年8月20日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
216

研究概览

简要总结

  1. 2016 results in https://www.ncbi.nlm.nih.gov/pubmed/26580307 (added 29/01/2019) 2. 2018 results in https://www.ncbi.nlm.nih.gov/pubmed/30063303 (added 29/01/2019)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Male and female outpatients aged 19 - 60 years
  • 2. Patients will meet Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for major depressive disorder as determined by the mood disorders section of the Mini International Neuropsychiatric Interview (MINI)
  • 3. A score of 20 or greater on the Hamilton Depression Rating Scale (Ham-D), indicating at least moderately severe depression
  • 4. Competency to give informed consent

排除标准

  • 1. Pregnant women, lactating women and sexually active women of childbearing potential who are not using medically accepted means of contraception
  • 2. Serious suicidal risks as judged by the clinician and the MINI
  • 3. The following DSM-IV diagnoses (to ensure a homogeneous diagnostic group): organic mental disorders; substance abuse/dependence, including alcohol, active within the last year; schizophrenia, paranoid, or delusional disorders; other psychotic disorders; panic disorder or generalised anxiety disorder, if a primary diagnosis; obsessive-compulsive disorder or post-traumatic stress disorder; bipolar disorder; bulimia nervosa or anorexia nervosa
  • 4. Serious illness including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic and haematologic disease that is not stabilised, or a past history of convulsions
  • 5. Any retinal disease or systemic illness with active retinal involvement (e.g. diabetes) that precludes the use of bright light
  • 6. Patients who have a history of severe allergies and multiple drug adverse reactions
  • 7. Regular or current use of other psychotropic drugs, including lithium and tryptophan
  • 8. Patients treated with beta blocking drugs
  • 9. Hypertensive patients being treated with guanethidine, reserpine, clonidine or methyldopa (because of possible mood-altering effects of those drugs)
  • 10. Use of monoamine oxidase inhibitors within 14 days of Visit 1 (to ensure no drug interactions between fluoxetine and MAOIs), or use of heterocyclic antidepressants within 7 days of Visit 1 (to ensure adequate washout period of two weeks between stopping previous drug and start of treatment at Visit 2)
  • 11. Previous use of fluoxetine or light therapy
  • 12. Treatment resistance in the current episode, as defined by failure (lack of clinically significant response) of two or more antidepressants given at therapeutic doses for at least 6 weeks
  • 13. Patients who start formal psychotherapy (e.g. cognitive-behavioural or interpersonal psychotherapy) within 3 months of Visit 1, or who plan to initiate such psychotherapy during this study
  • 14. Patients involved in any other form of treatment for depression

研究者

发起方
niversity of British Columbia (Canada)

相似试验